When treating a patient with multiple myeloma with bortezomib, how do you decide between subcutaneous vs intravenous dosing?

Due to the markedly increased risk of of peripheral neuropathy, the standard of care worldwide is to utilize subcutaneous bortezomib. There really is no medical indication to prefer IV over SQ. The issue of weekly versus biweekly bortezomib is controversial. The FDA indication is for biweekly on day...

I never use bortezomib iv

The only time I would use IV Velcade is when pt has severe skin reaction to sc.